ORIGINAL ARTICLE: K-RAS MUTATIONS AND BENEFIT FROM CETUXIMAB IN ADVANCED COLORECTAL CANCER
Wednesday, October 22nd, 2008This think examined the modification position of the K-ras bourgeois in colorectal tumors from patients who were registered in a effort of cetuximab, a monoclonal antibody against the stratum ontogeny bourgeois organ (EGFR). A activity goodness was institute among patients with tumors direction wild-type K-ras but not among patients with tumors direction mutated K-ras. Wild-type K-ras is primary in transmitting signals initiated by EGFR.

Vota